Suppr超能文献

利用体液进行胰腺癌早期检测的分子方法

Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer.

作者信息

Satoh Kennichi

机构信息

Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi 983-8536, Japan.

出版信息

Diagnostics (Basel). 2021 Feb 22;11(2):375. doi: 10.3390/diagnostics11020375.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most malignant form of gastrointestinal tumor and is the fourth leading cause of deaths due to cancer in Japan. This cancer shows a poor outcome due to the difficulty of its early diagnosis and its rapid growth. Once this disease becomes clinically evident, it is frequently accompanied by distant metastasis at the time of diagnosis. A recent multicenter study in Japan revealed that patients with the early stage of this disease (stage 0 and I) showed favorable prognosis after surgical resection, indicating the importance of early detection for improvement of PDAC prognosis. PDAC develops through a stepwise progression from the precursor lesion, and over the last few decades molecular analyses have shown the detailed genetic alterations that occur in this process. Since advances in molecular technologies have enabled the detection of genetic changes from a very small quantity of samples, a large number of non-invasive molecular approaches have been utilized in an attempt to find precursor or non-invasive carcinoma lesions. In this review, the current efforts in terms of the molecular approaches applied for the early detection of PDAC-especially using body fluids such as pancreatic juice, blood, and saliva-are summarized.

摘要

胰腺导管腺癌(PDAC)是胃肠道肿瘤中恶性程度最高的类型,在日本是癌症死亡的第四大主要原因。由于早期诊断困难且生长迅速,这种癌症的预后较差。一旦该病在临床上变得明显,在诊断时常常伴有远处转移。日本最近的一项多中心研究表明,处于该病早期阶段(0期和I期)的患者在手术切除后显示出良好的预后,这表明早期检测对于改善PDAC预后的重要性。PDAC是从前体病变逐步发展而来的,在过去几十年中,分子分析已经揭示了这一过程中发生的详细基因改变。由于分子技术的进步使得能够从极少量样本中检测到基因变化,大量非侵入性分子方法已被用于试图找到前体或非侵入性癌病变。在这篇综述中,总结了目前在应用分子方法早期检测PDAC方面所做的努力,特别是使用胰液、血液和唾液等体液进行检测的方法。

相似文献

1
Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer.
Diagnostics (Basel). 2021 Feb 22;11(2):375. doi: 10.3390/diagnostics11020375.
2
Advances in Early Detection of Pancreatic Cancer.
Diagnostics (Basel). 2019 Feb 5;9(1):18. doi: 10.3390/diagnostics9010018.
3
Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
BMC Genomics. 2015;16 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-2164-16-S1-S1. Epub 2015 Jan 15.
4
Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples.
Diagnostics (Basel). 2020 Dec 6;10(12):1056. doi: 10.3390/diagnostics10121056.
5
MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.
World J Gastrointest Oncol. 2016 Jan 15;8(1):18-29. doi: 10.4251/wjgo.v8.i1.18.
6
7
Current status of molecular diagnostic approaches using liquid biopsy.
J Gastroenterol. 2023 Sep;58(9):834-847. doi: 10.1007/s00535-023-02024-4. Epub 2023 Jul 20.
8
[Early stage pancreatic cancer].
Chirurg. 2018 Apr;89(4):257-265. doi: 10.1007/s00104-017-0569-y.
9
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
10
Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances.
Cureus. 2022 Sep 23;14(9):e29485. doi: 10.7759/cureus.29485. eCollection 2022 Sep.

引用本文的文献

2
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.
Cells. 2024 Mar 29;13(7):602. doi: 10.3390/cells13070602.
3
Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation.
Mol Cancer. 2023 Oct 6;22(1):167. doi: 10.1186/s12943-023-01870-3.
4
Earlier Diagnosis of Pancreatic Cancer: Is It Possible?
Cancers (Basel). 2023 Sep 5;15(18):4430. doi: 10.3390/cancers15184430.
5
Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe.
World J Gastroenterol. 2022 Aug 21;28(31):4235-4248. doi: 10.3748/wjg.v28.i31.4235.
6
Pancreatic cancer in 2021: What you need to know to win.
World J Gastroenterol. 2021 Sep 21;27(35):5851-5889. doi: 10.3748/wjg.v27.i35.5851.
7
Graphene-Assisted Electrochemical Sensor for Detection of Pancreatic Cancer Markers.
Front Chem. 2021 Aug 19;9:733371. doi: 10.3389/fchem.2021.733371. eCollection 2021.
8
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Cancers (Basel). 2021 Apr 20;13(8):1986. doi: 10.3390/cancers13081986.

本文引用的文献

2
Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
J Gastroenterol. 2020 Dec;55(12):1183-1193. doi: 10.1007/s00535-020-01724-5. Epub 2020 Sep 16.
3
Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
J Mol Diagn. 2020 Jun;22(6):748-756. doi: 10.1016/j.jmoldx.2020.02.010. Epub 2020 Mar 20.
4
Serum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
J Cancer. 2020 Jan 1;11(6):1325-1333. doi: 10.7150/jca.38048. eCollection 2020.
6
Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.
Am J Pathol. 2019 Jan;189(1):71-81. doi: 10.1016/j.ajpath.2018.03.020.
7
Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.
8
Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer.
Sci Rep. 2018 Nov 6;8(1):16389. doi: 10.1038/s41598-018-34597-z.
9
Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
J Clin Oncol. 2018 Oct 1;36(28):2887-2894. doi: 10.1200/JCO.2017.77.6658. Epub 2018 Aug 14.
10
Detection and localization of surgically resectable cancers with a multi-analyte blood test.
Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验